Review





Similar Products

94
Croda International Plc oh c22
Oh C22, supplied by Croda International Plc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/oh c22/product/Croda International Plc
Average 94 stars, based on 1 article reviews
oh c22 - by Bioz Stars, 2026-06
94/100 stars
  Buy from Supplier

94
Croda International Plc c22 ceramide
C22 Ceramide, supplied by Croda International Plc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/c22 ceramide/product/Croda International Plc
Average 94 stars, based on 1 article reviews
c22 ceramide - by Bioz Stars, 2026-06
94/100 stars
  Buy from Supplier

94
Croda International Plc n behenoyl d erythro sphingosine
N Behenoyl D Erythro Sphingosine, supplied by Croda International Plc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/n behenoyl d erythro sphingosine/product/Croda International Plc
Average 94 stars, based on 1 article reviews
n behenoyl d erythro sphingosine - by Bioz Stars, 2026-06
94/100 stars
  Buy from Supplier

90
Cayman Chemical c22 ceramide (d18:1/22:0) c40h79no3
C22 Ceramide (D18:1/22:0) C40h79no3, supplied by Cayman Chemical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/c22 ceramide (d18:1/22:0) c40h79no3/product/Cayman Chemical
Average 90 stars, based on 1 article reviews
c22 ceramide (d18:1/22:0) c40h79no3 - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier

90
Cayman Chemical c22 ceramide (d18:1/22:0)
a . Principal component analysis (PCA) of targeted metabolomics experiment on 7940B cells treated with DMSO, apilimod (100 nM), or ESK981 (1000 nM) for eight hours. b . Citrate levels as detected by LC-MS-based metabolomics on 7940B cells treated with apilimod (100 nM) or ESK981 (1000 nM) for either three or eight hours, as indicated. Bars are +/-SD. (One-way ANOVA with Dunnett’s.). c . Heatmap of glycolytic metabolite abundance in 7940B cells treated with DMSO, apilimod (100 nM), or ESK981 (1000 nM) for eight hours. G6P = glucose 6-phosphate; F6P = fructose 6-phosphate; FBP = fructose 1,6-bisphosphate; DHAP = dihydroxyacetone phosphate; G3P = glyceraldehyde 3-phosphate; 2PG = 2 phosphoglycerate; PEP = phosphoenolpyruvate. (One-way ANOVA with Dunnett’s.) The same data is represented in (d) . d . Heatmap of significantly changed metabolites as determined by unpaired two-tailed t-test (apilimod vs DMSO or ESK981 vs DMSO, p < 0.05 in at least one of the two comparisons). Biological triplicates are displayed. e . PCA of targeted lipidomics experiment on 7940B cells treated with DMSO, apilimod (100 nM), or ESK981 (1000 nM) for 24 hours. Of note, one sample in the apilimod group was removed as an outlier. f . Forest plot indicating changes in lipid class abundance in 7940B cells upon treatment with DMSO, apilimod (100 nM), or ESK981 (1000 nM) for 24 hours. HexCer = hexosylceramide; SM = sphingomyelin; PI= phosphatidylinositol; Cer = <t>ceramide;</t> AC= acylcarnitine; PC= phosphatidylcholine; DG = diacylglyceride; FA = fatty acid; PE = phosphatidylethanolamine; LPC = lysophosphatidylcholine; CE = cholesteryl ester; LPE = lipophosphatidylethanolamine; TG = triacylglyceride. Effect sizes are in log2 scale of lipid abundance estimated from separate linear model for each treatment (apilimod or ESK981) compared to DMSO, adjusting for lipid classes with random intercept. Bars are 95% CI. g-h . Volcano plot showing differentially abundant lipid species in 7940B cells upon treatment with apilimod (100 nM, g ) or ESK981 (1000 nM, h ) for 24 hours. Highlighted in red are upregulated sphingolipid species. Highlighted in blue are downregulated sphingolipid species. (Two-tailed t-test using BH procedure to calculate FDR.). i . PCA of targeted lipidomics experiment on 7940B cells treated with DMSO, apilimod (100 nM), ESK981 (1000 nM), fatostatin (20 μM), apilimod + fatostatin, or ESK981 + fatostatin for 24 hours. Arrows are provided to highlight the change in lipid profile upon addition of fatostatin to apilimod or ESK981. Of note, data from one sample of the DSMO group was removed due to being a statistical outlier. j . Relative abundance of ceramides (left) and hexosylceramides (right) in 7940B cells upon treatment with apilimod (100 nM), ESK981 (1000 nM), fatostatin (20 μM), apilimod + fatostatin, or ESK+ fatostatin for 24 hours. (Unpaired two-tailed t-tests.). k . C20 ceramide <t>(d18:1/20:0)</t> isotopologue distribution in 7940B cells upon incubation with U- 13 C 6 glucose and treatment with DMSO, apilimod (100 nM), or ESK91 (1000 nM) for 24 hours. Bars represent the range. l . Fractional enrichment pattern in C20 ceramide (d18:1/20:0) in 7940B cells upon incubation with U- 13 C 6 glucose and treatment with DMSO, apilimod (100 nM), or ESK981 (1000 nM) for 24 hours, binned as indicated. Bars are +/-SD. (Two-way ANOVA with Dunnett’s with DMSO as the baseline.). m . Total ion counts of individual isotopologues of C20 ceramide (d18:1/20:0) in 7940B cells upon incubation with U- 13 C 6 glucose and treatment with DMSO, apilimod (100 nM), or ESK981 (1000 nM). This is the pre-normalized data from (l) . Bars represent the range. n . C20 ceramide (d18:1/20:0) isotopologue distribution in 7940B cells upon incubation with 12 C 6 glucose and treatment with DMSO, apilimod (100 nM), or ESK91 (1000 nM) for 24 hours. Extraneous peaks were detected at M + 12-14 and M + 30-32 which are suspected to be contaminating species that were co-eluted with our target species. o . Fractional enrichment pattern in <t>C22</t> ceramide (d18:1/22:0) in 7940B cells upon incubation with U- 13 C 6 glucose and treatment with DMSO, apilimod (100 nM), or ESK91 (1000 nM) for 24 hours. Bars represent the range. p . Data from (o) binned as indicated. Bars are +/-SD. (Two-way ANOVA with Dunnett’s.). q . Total ion counts of individual isotopologues of C22 ceramide (d18:1/22:0) in 7940B cells upon incubation with U- 13 C 6 glucose and treatment with DMSO, apilimod (100 nM), or ESK981 (1000 nM). This is the pre-normalized data from (o) . Bars represent the range. r . C22 ceramide (d18:1/22:0) isotopologue distribution in 7940B cells upon incubation with 12 C 6 glucose and treatment with DMSO, apilimod (100 nM), or ESK981 (1000 nM) for 24 hours. Extraneous peaks were detected at M + 12-14 which is suspected to be a contaminating species that were co-eluted with our target species. Statistics and reproducibility: b . n = 3 biological replicates. c . * indicates p < 0.05, ** indicates p < 0.01, *** indicates p < 0.001, **** indicates p < 0.0001. P-values: G6P: DMSO vs apilimod:9.0e-4; DMSO vs ESK981:2.6e-5; F6P: DMSO vs apilimod:5.5e-4; DMSO vs ESK981:2.6e-5; FBP: DMSO vs apilimod:0.007; DMSO vs ESK981:0.002; DHAP: DMSO vs apilimod:6.8e-6; DMSO vs ESK981:3.1e-7; G3P: DMSO vs apilimod:1.2e-4; DMSO vs ESK981:4.1e-5; 2PG: DMSO vs apilimod:8.2e-4; DMSO vs ESK981:7.2e-5; PEP: DMSO vs apilimod:6.9e-6; DMSO vs ESK981:1.5e-7. f-h . n = 4 biological replicates for DMSO and ESK981; n = 3 biological replicates for apilimod. i ; n = 4 biological replicates per group for AP, ESK, Fato, AP+Fato, and ESK+Fato groups, n = 3 for the DMSO group. j . n = 4 biological replicates per group for AP, ESK, Fato, AP+Fato, and ESK+Fato groups, n = 3 for the DMSO group. P-values: Ceramides: ESK981 vs ESK981 + fatostatin:2.6e-39. k . n = 3 biological replicates per group. l . n = 3 biological replicates per group. P-values: M + 10-M + 19: DMSO vs AP:0.031; DMSO vs ESK:0.040; M + 30-M + 38: DMSO vs AP:0.0021; DMSO vs ESK:0.034. m . n = 3 biological replicates each. o . n = 3 biological replicates per group. p . n = 3 biological replicates per group. P-value: M + 30-M + 40: apilimod vs DMSO:0.013. q . n = 3 biological replicates per group.
C22 Ceramide (D18:1/22:0), supplied by Cayman Chemical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/c22 ceramide (d18:1/22:0)/product/Cayman Chemical
Average 90 stars, based on 1 article reviews
c22 ceramide (d18:1/22:0) - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier

94
Croda International Plc 860501p
a . Principal component analysis (PCA) of targeted metabolomics experiment on 7940B cells treated with DMSO, apilimod (100 nM), or ESK981 (1000 nM) for eight hours. b . Citrate levels as detected by LC-MS-based metabolomics on 7940B cells treated with apilimod (100 nM) or ESK981 (1000 nM) for either three or eight hours, as indicated. Bars are +/-SD. (One-way ANOVA with Dunnett’s.). c . Heatmap of glycolytic metabolite abundance in 7940B cells treated with DMSO, apilimod (100 nM), or ESK981 (1000 nM) for eight hours. G6P = glucose 6-phosphate; F6P = fructose 6-phosphate; FBP = fructose 1,6-bisphosphate; DHAP = dihydroxyacetone phosphate; G3P = glyceraldehyde 3-phosphate; 2PG = 2 phosphoglycerate; PEP = phosphoenolpyruvate. (One-way ANOVA with Dunnett’s.) The same data is represented in (d) . d . Heatmap of significantly changed metabolites as determined by unpaired two-tailed t-test (apilimod vs DMSO or ESK981 vs DMSO, p < 0.05 in at least one of the two comparisons). Biological triplicates are displayed. e . PCA of targeted lipidomics experiment on 7940B cells treated with DMSO, apilimod (100 nM), or ESK981 (1000 nM) for 24 hours. Of note, one sample in the apilimod group was removed as an outlier. f . Forest plot indicating changes in lipid class abundance in 7940B cells upon treatment with DMSO, apilimod (100 nM), or ESK981 (1000 nM) for 24 hours. HexCer = hexosylceramide; SM = sphingomyelin; PI= phosphatidylinositol; Cer = <t>ceramide;</t> AC= acylcarnitine; PC= phosphatidylcholine; DG = diacylglyceride; FA = fatty acid; PE = phosphatidylethanolamine; LPC = lysophosphatidylcholine; CE = cholesteryl ester; LPE = lipophosphatidylethanolamine; TG = triacylglyceride. Effect sizes are in log2 scale of lipid abundance estimated from separate linear model for each treatment (apilimod or ESK981) compared to DMSO, adjusting for lipid classes with random intercept. Bars are 95% CI. g-h . Volcano plot showing differentially abundant lipid species in 7940B cells upon treatment with apilimod (100 nM, g ) or ESK981 (1000 nM, h ) for 24 hours. Highlighted in red are upregulated sphingolipid species. Highlighted in blue are downregulated sphingolipid species. (Two-tailed t-test using BH procedure to calculate FDR.). i . PCA of targeted lipidomics experiment on 7940B cells treated with DMSO, apilimod (100 nM), ESK981 (1000 nM), fatostatin (20 μM), apilimod + fatostatin, or ESK981 + fatostatin for 24 hours. Arrows are provided to highlight the change in lipid profile upon addition of fatostatin to apilimod or ESK981. Of note, data from one sample of the DSMO group was removed due to being a statistical outlier. j . Relative abundance of ceramides (left) and hexosylceramides (right) in 7940B cells upon treatment with apilimod (100 nM), ESK981 (1000 nM), fatostatin (20 μM), apilimod + fatostatin, or ESK+ fatostatin for 24 hours. (Unpaired two-tailed t-tests.). k . C20 ceramide <t>(d18:1/20:0)</t> isotopologue distribution in 7940B cells upon incubation with U- 13 C 6 glucose and treatment with DMSO, apilimod (100 nM), or ESK91 (1000 nM) for 24 hours. Bars represent the range. l . Fractional enrichment pattern in C20 ceramide (d18:1/20:0) in 7940B cells upon incubation with U- 13 C 6 glucose and treatment with DMSO, apilimod (100 nM), or ESK981 (1000 nM) for 24 hours, binned as indicated. Bars are +/-SD. (Two-way ANOVA with Dunnett’s with DMSO as the baseline.). m . Total ion counts of individual isotopologues of C20 ceramide (d18:1/20:0) in 7940B cells upon incubation with U- 13 C 6 glucose and treatment with DMSO, apilimod (100 nM), or ESK981 (1000 nM). This is the pre-normalized data from (l) . Bars represent the range. n . C20 ceramide (d18:1/20:0) isotopologue distribution in 7940B cells upon incubation with 12 C 6 glucose and treatment with DMSO, apilimod (100 nM), or ESK91 (1000 nM) for 24 hours. Extraneous peaks were detected at M + 12-14 and M + 30-32 which are suspected to be contaminating species that were co-eluted with our target species. o . Fractional enrichment pattern in <t>C22</t> ceramide (d18:1/22:0) in 7940B cells upon incubation with U- 13 C 6 glucose and treatment with DMSO, apilimod (100 nM), or ESK91 (1000 nM) for 24 hours. Bars represent the range. p . Data from (o) binned as indicated. Bars are +/-SD. (Two-way ANOVA with Dunnett’s.). q . Total ion counts of individual isotopologues of C22 ceramide (d18:1/22:0) in 7940B cells upon incubation with U- 13 C 6 glucose and treatment with DMSO, apilimod (100 nM), or ESK981 (1000 nM). This is the pre-normalized data from (o) . Bars represent the range. r . C22 ceramide (d18:1/22:0) isotopologue distribution in 7940B cells upon incubation with 12 C 6 glucose and treatment with DMSO, apilimod (100 nM), or ESK981 (1000 nM) for 24 hours. Extraneous peaks were detected at M + 12-14 which is suspected to be a contaminating species that were co-eluted with our target species. Statistics and reproducibility: b . n = 3 biological replicates. c . * indicates p < 0.05, ** indicates p < 0.01, *** indicates p < 0.001, **** indicates p < 0.0001. P-values: G6P: DMSO vs apilimod:9.0e-4; DMSO vs ESK981:2.6e-5; F6P: DMSO vs apilimod:5.5e-4; DMSO vs ESK981:2.6e-5; FBP: DMSO vs apilimod:0.007; DMSO vs ESK981:0.002; DHAP: DMSO vs apilimod:6.8e-6; DMSO vs ESK981:3.1e-7; G3P: DMSO vs apilimod:1.2e-4; DMSO vs ESK981:4.1e-5; 2PG: DMSO vs apilimod:8.2e-4; DMSO vs ESK981:7.2e-5; PEP: DMSO vs apilimod:6.9e-6; DMSO vs ESK981:1.5e-7. f-h . n = 4 biological replicates for DMSO and ESK981; n = 3 biological replicates for apilimod. i ; n = 4 biological replicates per group for AP, ESK, Fato, AP+Fato, and ESK+Fato groups, n = 3 for the DMSO group. j . n = 4 biological replicates per group for AP, ESK, Fato, AP+Fato, and ESK+Fato groups, n = 3 for the DMSO group. P-values: Ceramides: ESK981 vs ESK981 + fatostatin:2.6e-39. k . n = 3 biological replicates per group. l . n = 3 biological replicates per group. P-values: M + 10-M + 19: DMSO vs AP:0.031; DMSO vs ESK:0.040; M + 30-M + 38: DMSO vs AP:0.0021; DMSO vs ESK:0.034. m . n = 3 biological replicates each. o . n = 3 biological replicates per group. p . n = 3 biological replicates per group. P-value: M + 30-M + 40: apilimod vs DMSO:0.013. q . n = 3 biological replicates per group.
860501p, supplied by Croda International Plc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/860501p/product/Croda International Plc
Average 94 stars, based on 1 article reviews
860501p - by Bioz Stars, 2026-06
94/100 stars
  Buy from Supplier

94
Croda International Plc cer d18
a . Principal component analysis (PCA) of targeted metabolomics experiment on 7940B cells treated with DMSO, apilimod (100 nM), or ESK981 (1000 nM) for eight hours. b . Citrate levels as detected by LC-MS-based metabolomics on 7940B cells treated with apilimod (100 nM) or ESK981 (1000 nM) for either three or eight hours, as indicated. Bars are +/-SD. (One-way ANOVA with Dunnett’s.). c . Heatmap of glycolytic metabolite abundance in 7940B cells treated with DMSO, apilimod (100 nM), or ESK981 (1000 nM) for eight hours. G6P = glucose 6-phosphate; F6P = fructose 6-phosphate; FBP = fructose 1,6-bisphosphate; DHAP = dihydroxyacetone phosphate; G3P = glyceraldehyde 3-phosphate; 2PG = 2 phosphoglycerate; PEP = phosphoenolpyruvate. (One-way ANOVA with Dunnett’s.) The same data is represented in (d) . d . Heatmap of significantly changed metabolites as determined by unpaired two-tailed t-test (apilimod vs DMSO or ESK981 vs DMSO, p < 0.05 in at least one of the two comparisons). Biological triplicates are displayed. e . PCA of targeted lipidomics experiment on 7940B cells treated with DMSO, apilimod (100 nM), or ESK981 (1000 nM) for 24 hours. Of note, one sample in the apilimod group was removed as an outlier. f . Forest plot indicating changes in lipid class abundance in 7940B cells upon treatment with DMSO, apilimod (100 nM), or ESK981 (1000 nM) for 24 hours. HexCer = hexosylceramide; SM = sphingomyelin; PI= phosphatidylinositol; Cer = <t>ceramide;</t> AC= acylcarnitine; PC= phosphatidylcholine; DG = diacylglyceride; FA = fatty acid; PE = phosphatidylethanolamine; LPC = lysophosphatidylcholine; CE = cholesteryl ester; LPE = lipophosphatidylethanolamine; TG = triacylglyceride. Effect sizes are in log2 scale of lipid abundance estimated from separate linear model for each treatment (apilimod or ESK981) compared to DMSO, adjusting for lipid classes with random intercept. Bars are 95% CI. g-h . Volcano plot showing differentially abundant lipid species in 7940B cells upon treatment with apilimod (100 nM, g ) or ESK981 (1000 nM, h ) for 24 hours. Highlighted in red are upregulated sphingolipid species. Highlighted in blue are downregulated sphingolipid species. (Two-tailed t-test using BH procedure to calculate FDR.). i . PCA of targeted lipidomics experiment on 7940B cells treated with DMSO, apilimod (100 nM), ESK981 (1000 nM), fatostatin (20 μM), apilimod + fatostatin, or ESK981 + fatostatin for 24 hours. Arrows are provided to highlight the change in lipid profile upon addition of fatostatin to apilimod or ESK981. Of note, data from one sample of the DSMO group was removed due to being a statistical outlier. j . Relative abundance of ceramides (left) and hexosylceramides (right) in 7940B cells upon treatment with apilimod (100 nM), ESK981 (1000 nM), fatostatin (20 μM), apilimod + fatostatin, or ESK+ fatostatin for 24 hours. (Unpaired two-tailed t-tests.). k . C20 ceramide <t>(d18:1/20:0)</t> isotopologue distribution in 7940B cells upon incubation with U- 13 C 6 glucose and treatment with DMSO, apilimod (100 nM), or ESK91 (1000 nM) for 24 hours. Bars represent the range. l . Fractional enrichment pattern in C20 ceramide (d18:1/20:0) in 7940B cells upon incubation with U- 13 C 6 glucose and treatment with DMSO, apilimod (100 nM), or ESK981 (1000 nM) for 24 hours, binned as indicated. Bars are +/-SD. (Two-way ANOVA with Dunnett’s with DMSO as the baseline.). m . Total ion counts of individual isotopologues of C20 ceramide (d18:1/20:0) in 7940B cells upon incubation with U- 13 C 6 glucose and treatment with DMSO, apilimod (100 nM), or ESK981 (1000 nM). This is the pre-normalized data from (l) . Bars represent the range. n . C20 ceramide (d18:1/20:0) isotopologue distribution in 7940B cells upon incubation with 12 C 6 glucose and treatment with DMSO, apilimod (100 nM), or ESK91 (1000 nM) for 24 hours. Extraneous peaks were detected at M + 12-14 and M + 30-32 which are suspected to be contaminating species that were co-eluted with our target species. o . Fractional enrichment pattern in <t>C22</t> ceramide (d18:1/22:0) in 7940B cells upon incubation with U- 13 C 6 glucose and treatment with DMSO, apilimod (100 nM), or ESK91 (1000 nM) for 24 hours. Bars represent the range. p . Data from (o) binned as indicated. Bars are +/-SD. (Two-way ANOVA with Dunnett’s.). q . Total ion counts of individual isotopologues of C22 ceramide (d18:1/22:0) in 7940B cells upon incubation with U- 13 C 6 glucose and treatment with DMSO, apilimod (100 nM), or ESK981 (1000 nM). This is the pre-normalized data from (o) . Bars represent the range. r . C22 ceramide (d18:1/22:0) isotopologue distribution in 7940B cells upon incubation with 12 C 6 glucose and treatment with DMSO, apilimod (100 nM), or ESK981 (1000 nM) for 24 hours. Extraneous peaks were detected at M + 12-14 which is suspected to be a contaminating species that were co-eluted with our target species. Statistics and reproducibility: b . n = 3 biological replicates. c . * indicates p < 0.05, ** indicates p < 0.01, *** indicates p < 0.001, **** indicates p < 0.0001. P-values: G6P: DMSO vs apilimod:9.0e-4; DMSO vs ESK981:2.6e-5; F6P: DMSO vs apilimod:5.5e-4; DMSO vs ESK981:2.6e-5; FBP: DMSO vs apilimod:0.007; DMSO vs ESK981:0.002; DHAP: DMSO vs apilimod:6.8e-6; DMSO vs ESK981:3.1e-7; G3P: DMSO vs apilimod:1.2e-4; DMSO vs ESK981:4.1e-5; 2PG: DMSO vs apilimod:8.2e-4; DMSO vs ESK981:7.2e-5; PEP: DMSO vs apilimod:6.9e-6; DMSO vs ESK981:1.5e-7. f-h . n = 4 biological replicates for DMSO and ESK981; n = 3 biological replicates for apilimod. i ; n = 4 biological replicates per group for AP, ESK, Fato, AP+Fato, and ESK+Fato groups, n = 3 for the DMSO group. j . n = 4 biological replicates per group for AP, ESK, Fato, AP+Fato, and ESK+Fato groups, n = 3 for the DMSO group. P-values: Ceramides: ESK981 vs ESK981 + fatostatin:2.6e-39. k . n = 3 biological replicates per group. l . n = 3 biological replicates per group. P-values: M + 10-M + 19: DMSO vs AP:0.031; DMSO vs ESK:0.040; M + 30-M + 38: DMSO vs AP:0.0021; DMSO vs ESK:0.034. m . n = 3 biological replicates each. o . n = 3 biological replicates per group. p . n = 3 biological replicates per group. P-value: M + 30-M + 40: apilimod vs DMSO:0.013. q . n = 3 biological replicates per group.
Cer D18, supplied by Croda International Plc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cer d18/product/Croda International Plc
Average 94 stars, based on 1 article reviews
cer d18 - by Bioz Stars, 2026-06
94/100 stars
  Buy from Supplier

94
Croda International Plc avanti polar lipids 860501
a . Principal component analysis (PCA) of targeted metabolomics experiment on 7940B cells treated with DMSO, apilimod (100 nM), or ESK981 (1000 nM) for eight hours. b . Citrate levels as detected by LC-MS-based metabolomics on 7940B cells treated with apilimod (100 nM) or ESK981 (1000 nM) for either three or eight hours, as indicated. Bars are +/-SD. (One-way ANOVA with Dunnett’s.). c . Heatmap of glycolytic metabolite abundance in 7940B cells treated with DMSO, apilimod (100 nM), or ESK981 (1000 nM) for eight hours. G6P = glucose 6-phosphate; F6P = fructose 6-phosphate; FBP = fructose 1,6-bisphosphate; DHAP = dihydroxyacetone phosphate; G3P = glyceraldehyde 3-phosphate; 2PG = 2 phosphoglycerate; PEP = phosphoenolpyruvate. (One-way ANOVA with Dunnett’s.) The same data is represented in (d) . d . Heatmap of significantly changed metabolites as determined by unpaired two-tailed t-test (apilimod vs DMSO or ESK981 vs DMSO, p < 0.05 in at least one of the two comparisons). Biological triplicates are displayed. e . PCA of targeted lipidomics experiment on 7940B cells treated with DMSO, apilimod (100 nM), or ESK981 (1000 nM) for 24 hours. Of note, one sample in the apilimod group was removed as an outlier. f . Forest plot indicating changes in lipid class abundance in 7940B cells upon treatment with DMSO, apilimod (100 nM), or ESK981 (1000 nM) for 24 hours. HexCer = hexosylceramide; SM = sphingomyelin; PI= phosphatidylinositol; Cer = <t>ceramide;</t> AC= acylcarnitine; PC= phosphatidylcholine; DG = diacylglyceride; FA = fatty acid; PE = phosphatidylethanolamine; LPC = lysophosphatidylcholine; CE = cholesteryl ester; LPE = lipophosphatidylethanolamine; TG = triacylglyceride. Effect sizes are in log2 scale of lipid abundance estimated from separate linear model for each treatment (apilimod or ESK981) compared to DMSO, adjusting for lipid classes with random intercept. Bars are 95% CI. g-h . Volcano plot showing differentially abundant lipid species in 7940B cells upon treatment with apilimod (100 nM, g ) or ESK981 (1000 nM, h ) for 24 hours. Highlighted in red are upregulated sphingolipid species. Highlighted in blue are downregulated sphingolipid species. (Two-tailed t-test using BH procedure to calculate FDR.). i . PCA of targeted lipidomics experiment on 7940B cells treated with DMSO, apilimod (100 nM), ESK981 (1000 nM), fatostatin (20 μM), apilimod + fatostatin, or ESK981 + fatostatin for 24 hours. Arrows are provided to highlight the change in lipid profile upon addition of fatostatin to apilimod or ESK981. Of note, data from one sample of the DSMO group was removed due to being a statistical outlier. j . Relative abundance of ceramides (left) and hexosylceramides (right) in 7940B cells upon treatment with apilimod (100 nM), ESK981 (1000 nM), fatostatin (20 μM), apilimod + fatostatin, or ESK+ fatostatin for 24 hours. (Unpaired two-tailed t-tests.). k . C20 ceramide <t>(d18:1/20:0)</t> isotopologue distribution in 7940B cells upon incubation with U- 13 C 6 glucose and treatment with DMSO, apilimod (100 nM), or ESK91 (1000 nM) for 24 hours. Bars represent the range. l . Fractional enrichment pattern in C20 ceramide (d18:1/20:0) in 7940B cells upon incubation with U- 13 C 6 glucose and treatment with DMSO, apilimod (100 nM), or ESK981 (1000 nM) for 24 hours, binned as indicated. Bars are +/-SD. (Two-way ANOVA with Dunnett’s with DMSO as the baseline.). m . Total ion counts of individual isotopologues of C20 ceramide (d18:1/20:0) in 7940B cells upon incubation with U- 13 C 6 glucose and treatment with DMSO, apilimod (100 nM), or ESK981 (1000 nM). This is the pre-normalized data from (l) . Bars represent the range. n . C20 ceramide (d18:1/20:0) isotopologue distribution in 7940B cells upon incubation with 12 C 6 glucose and treatment with DMSO, apilimod (100 nM), or ESK91 (1000 nM) for 24 hours. Extraneous peaks were detected at M + 12-14 and M + 30-32 which are suspected to be contaminating species that were co-eluted with our target species. o . Fractional enrichment pattern in <t>C22</t> ceramide (d18:1/22:0) in 7940B cells upon incubation with U- 13 C 6 glucose and treatment with DMSO, apilimod (100 nM), or ESK91 (1000 nM) for 24 hours. Bars represent the range. p . Data from (o) binned as indicated. Bars are +/-SD. (Two-way ANOVA with Dunnett’s.). q . Total ion counts of individual isotopologues of C22 ceramide (d18:1/22:0) in 7940B cells upon incubation with U- 13 C 6 glucose and treatment with DMSO, apilimod (100 nM), or ESK981 (1000 nM). This is the pre-normalized data from (o) . Bars represent the range. r . C22 ceramide (d18:1/22:0) isotopologue distribution in 7940B cells upon incubation with 12 C 6 glucose and treatment with DMSO, apilimod (100 nM), or ESK981 (1000 nM) for 24 hours. Extraneous peaks were detected at M + 12-14 which is suspected to be a contaminating species that were co-eluted with our target species. Statistics and reproducibility: b . n = 3 biological replicates. c . * indicates p < 0.05, ** indicates p < 0.01, *** indicates p < 0.001, **** indicates p < 0.0001. P-values: G6P: DMSO vs apilimod:9.0e-4; DMSO vs ESK981:2.6e-5; F6P: DMSO vs apilimod:5.5e-4; DMSO vs ESK981:2.6e-5; FBP: DMSO vs apilimod:0.007; DMSO vs ESK981:0.002; DHAP: DMSO vs apilimod:6.8e-6; DMSO vs ESK981:3.1e-7; G3P: DMSO vs apilimod:1.2e-4; DMSO vs ESK981:4.1e-5; 2PG: DMSO vs apilimod:8.2e-4; DMSO vs ESK981:7.2e-5; PEP: DMSO vs apilimod:6.9e-6; DMSO vs ESK981:1.5e-7. f-h . n = 4 biological replicates for DMSO and ESK981; n = 3 biological replicates for apilimod. i ; n = 4 biological replicates per group for AP, ESK, Fato, AP+Fato, and ESK+Fato groups, n = 3 for the DMSO group. j . n = 4 biological replicates per group for AP, ESK, Fato, AP+Fato, and ESK+Fato groups, n = 3 for the DMSO group. P-values: Ceramides: ESK981 vs ESK981 + fatostatin:2.6e-39. k . n = 3 biological replicates per group. l . n = 3 biological replicates per group. P-values: M + 10-M + 19: DMSO vs AP:0.031; DMSO vs ESK:0.040; M + 30-M + 38: DMSO vs AP:0.0021; DMSO vs ESK:0.034. m . n = 3 biological replicates each. o . n = 3 biological replicates per group. p . n = 3 biological replicates per group. P-value: M + 30-M + 40: apilimod vs DMSO:0.013. q . n = 3 biological replicates per group.
Avanti Polar Lipids 860501, supplied by Croda International Plc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/avanti polar lipids 860501/product/Croda International Plc
Average 94 stars, based on 1 article reviews
avanti polar lipids 860501 - by Bioz Stars, 2026-06
94/100 stars
  Buy from Supplier

Image Search Results


a . Principal component analysis (PCA) of targeted metabolomics experiment on 7940B cells treated with DMSO, apilimod (100 nM), or ESK981 (1000 nM) for eight hours. b . Citrate levels as detected by LC-MS-based metabolomics on 7940B cells treated with apilimod (100 nM) or ESK981 (1000 nM) for either three or eight hours, as indicated. Bars are +/-SD. (One-way ANOVA with Dunnett’s.). c . Heatmap of glycolytic metabolite abundance in 7940B cells treated with DMSO, apilimod (100 nM), or ESK981 (1000 nM) for eight hours. G6P = glucose 6-phosphate; F6P = fructose 6-phosphate; FBP = fructose 1,6-bisphosphate; DHAP = dihydroxyacetone phosphate; G3P = glyceraldehyde 3-phosphate; 2PG = 2 phosphoglycerate; PEP = phosphoenolpyruvate. (One-way ANOVA with Dunnett’s.) The same data is represented in (d) . d . Heatmap of significantly changed metabolites as determined by unpaired two-tailed t-test (apilimod vs DMSO or ESK981 vs DMSO, p < 0.05 in at least one of the two comparisons). Biological triplicates are displayed. e . PCA of targeted lipidomics experiment on 7940B cells treated with DMSO, apilimod (100 nM), or ESK981 (1000 nM) for 24 hours. Of note, one sample in the apilimod group was removed as an outlier. f . Forest plot indicating changes in lipid class abundance in 7940B cells upon treatment with DMSO, apilimod (100 nM), or ESK981 (1000 nM) for 24 hours. HexCer = hexosylceramide; SM = sphingomyelin; PI= phosphatidylinositol; Cer = ceramide; AC= acylcarnitine; PC= phosphatidylcholine; DG = diacylglyceride; FA = fatty acid; PE = phosphatidylethanolamine; LPC = lysophosphatidylcholine; CE = cholesteryl ester; LPE = lipophosphatidylethanolamine; TG = triacylglyceride. Effect sizes are in log2 scale of lipid abundance estimated from separate linear model for each treatment (apilimod or ESK981) compared to DMSO, adjusting for lipid classes with random intercept. Bars are 95% CI. g-h . Volcano plot showing differentially abundant lipid species in 7940B cells upon treatment with apilimod (100 nM, g ) or ESK981 (1000 nM, h ) for 24 hours. Highlighted in red are upregulated sphingolipid species. Highlighted in blue are downregulated sphingolipid species. (Two-tailed t-test using BH procedure to calculate FDR.). i . PCA of targeted lipidomics experiment on 7940B cells treated with DMSO, apilimod (100 nM), ESK981 (1000 nM), fatostatin (20 μM), apilimod + fatostatin, or ESK981 + fatostatin for 24 hours. Arrows are provided to highlight the change in lipid profile upon addition of fatostatin to apilimod or ESK981. Of note, data from one sample of the DSMO group was removed due to being a statistical outlier. j . Relative abundance of ceramides (left) and hexosylceramides (right) in 7940B cells upon treatment with apilimod (100 nM), ESK981 (1000 nM), fatostatin (20 μM), apilimod + fatostatin, or ESK+ fatostatin for 24 hours. (Unpaired two-tailed t-tests.). k . C20 ceramide (d18:1/20:0) isotopologue distribution in 7940B cells upon incubation with U- 13 C 6 glucose and treatment with DMSO, apilimod (100 nM), or ESK91 (1000 nM) for 24 hours. Bars represent the range. l . Fractional enrichment pattern in C20 ceramide (d18:1/20:0) in 7940B cells upon incubation with U- 13 C 6 glucose and treatment with DMSO, apilimod (100 nM), or ESK981 (1000 nM) for 24 hours, binned as indicated. Bars are +/-SD. (Two-way ANOVA with Dunnett’s with DMSO as the baseline.). m . Total ion counts of individual isotopologues of C20 ceramide (d18:1/20:0) in 7940B cells upon incubation with U- 13 C 6 glucose and treatment with DMSO, apilimod (100 nM), or ESK981 (1000 nM). This is the pre-normalized data from (l) . Bars represent the range. n . C20 ceramide (d18:1/20:0) isotopologue distribution in 7940B cells upon incubation with 12 C 6 glucose and treatment with DMSO, apilimod (100 nM), or ESK91 (1000 nM) for 24 hours. Extraneous peaks were detected at M + 12-14 and M + 30-32 which are suspected to be contaminating species that were co-eluted with our target species. o . Fractional enrichment pattern in C22 ceramide (d18:1/22:0) in 7940B cells upon incubation with U- 13 C 6 glucose and treatment with DMSO, apilimod (100 nM), or ESK91 (1000 nM) for 24 hours. Bars represent the range. p . Data from (o) binned as indicated. Bars are +/-SD. (Two-way ANOVA with Dunnett’s.). q . Total ion counts of individual isotopologues of C22 ceramide (d18:1/22:0) in 7940B cells upon incubation with U- 13 C 6 glucose and treatment with DMSO, apilimod (100 nM), or ESK981 (1000 nM). This is the pre-normalized data from (o) . Bars represent the range. r . C22 ceramide (d18:1/22:0) isotopologue distribution in 7940B cells upon incubation with 12 C 6 glucose and treatment with DMSO, apilimod (100 nM), or ESK981 (1000 nM) for 24 hours. Extraneous peaks were detected at M + 12-14 which is suspected to be a contaminating species that were co-eluted with our target species. Statistics and reproducibility: b . n = 3 biological replicates. c . * indicates p < 0.05, ** indicates p < 0.01, *** indicates p < 0.001, **** indicates p < 0.0001. P-values: G6P: DMSO vs apilimod:9.0e-4; DMSO vs ESK981:2.6e-5; F6P: DMSO vs apilimod:5.5e-4; DMSO vs ESK981:2.6e-5; FBP: DMSO vs apilimod:0.007; DMSO vs ESK981:0.002; DHAP: DMSO vs apilimod:6.8e-6; DMSO vs ESK981:3.1e-7; G3P: DMSO vs apilimod:1.2e-4; DMSO vs ESK981:4.1e-5; 2PG: DMSO vs apilimod:8.2e-4; DMSO vs ESK981:7.2e-5; PEP: DMSO vs apilimod:6.9e-6; DMSO vs ESK981:1.5e-7. f-h . n = 4 biological replicates for DMSO and ESK981; n = 3 biological replicates for apilimod. i ; n = 4 biological replicates per group for AP, ESK, Fato, AP+Fato, and ESK+Fato groups, n = 3 for the DMSO group. j . n = 4 biological replicates per group for AP, ESK, Fato, AP+Fato, and ESK+Fato groups, n = 3 for the DMSO group. P-values: Ceramides: ESK981 vs ESK981 + fatostatin:2.6e-39. k . n = 3 biological replicates per group. l . n = 3 biological replicates per group. P-values: M + 10-M + 19: DMSO vs AP:0.031; DMSO vs ESK:0.040; M + 30-M + 38: DMSO vs AP:0.0021; DMSO vs ESK:0.034. m . n = 3 biological replicates each. o . n = 3 biological replicates per group. p . n = 3 biological replicates per group. P-value: M + 30-M + 40: apilimod vs DMSO:0.013. q . n = 3 biological replicates per group.

Journal: Nature

Article Title: Targeting PIKfyve-driven lipid metabolism in pancreatic cancer

doi: 10.1038/s41586-025-08917-z

Figure Lengend Snippet: a . Principal component analysis (PCA) of targeted metabolomics experiment on 7940B cells treated with DMSO, apilimod (100 nM), or ESK981 (1000 nM) for eight hours. b . Citrate levels as detected by LC-MS-based metabolomics on 7940B cells treated with apilimod (100 nM) or ESK981 (1000 nM) for either three or eight hours, as indicated. Bars are +/-SD. (One-way ANOVA with Dunnett’s.). c . Heatmap of glycolytic metabolite abundance in 7940B cells treated with DMSO, apilimod (100 nM), or ESK981 (1000 nM) for eight hours. G6P = glucose 6-phosphate; F6P = fructose 6-phosphate; FBP = fructose 1,6-bisphosphate; DHAP = dihydroxyacetone phosphate; G3P = glyceraldehyde 3-phosphate; 2PG = 2 phosphoglycerate; PEP = phosphoenolpyruvate. (One-way ANOVA with Dunnett’s.) The same data is represented in (d) . d . Heatmap of significantly changed metabolites as determined by unpaired two-tailed t-test (apilimod vs DMSO or ESK981 vs DMSO, p < 0.05 in at least one of the two comparisons). Biological triplicates are displayed. e . PCA of targeted lipidomics experiment on 7940B cells treated with DMSO, apilimod (100 nM), or ESK981 (1000 nM) for 24 hours. Of note, one sample in the apilimod group was removed as an outlier. f . Forest plot indicating changes in lipid class abundance in 7940B cells upon treatment with DMSO, apilimod (100 nM), or ESK981 (1000 nM) for 24 hours. HexCer = hexosylceramide; SM = sphingomyelin; PI= phosphatidylinositol; Cer = ceramide; AC= acylcarnitine; PC= phosphatidylcholine; DG = diacylglyceride; FA = fatty acid; PE = phosphatidylethanolamine; LPC = lysophosphatidylcholine; CE = cholesteryl ester; LPE = lipophosphatidylethanolamine; TG = triacylglyceride. Effect sizes are in log2 scale of lipid abundance estimated from separate linear model for each treatment (apilimod or ESK981) compared to DMSO, adjusting for lipid classes with random intercept. Bars are 95% CI. g-h . Volcano plot showing differentially abundant lipid species in 7940B cells upon treatment with apilimod (100 nM, g ) or ESK981 (1000 nM, h ) for 24 hours. Highlighted in red are upregulated sphingolipid species. Highlighted in blue are downregulated sphingolipid species. (Two-tailed t-test using BH procedure to calculate FDR.). i . PCA of targeted lipidomics experiment on 7940B cells treated with DMSO, apilimod (100 nM), ESK981 (1000 nM), fatostatin (20 μM), apilimod + fatostatin, or ESK981 + fatostatin for 24 hours. Arrows are provided to highlight the change in lipid profile upon addition of fatostatin to apilimod or ESK981. Of note, data from one sample of the DSMO group was removed due to being a statistical outlier. j . Relative abundance of ceramides (left) and hexosylceramides (right) in 7940B cells upon treatment with apilimod (100 nM), ESK981 (1000 nM), fatostatin (20 μM), apilimod + fatostatin, or ESK+ fatostatin for 24 hours. (Unpaired two-tailed t-tests.). k . C20 ceramide (d18:1/20:0) isotopologue distribution in 7940B cells upon incubation with U- 13 C 6 glucose and treatment with DMSO, apilimod (100 nM), or ESK91 (1000 nM) for 24 hours. Bars represent the range. l . Fractional enrichment pattern in C20 ceramide (d18:1/20:0) in 7940B cells upon incubation with U- 13 C 6 glucose and treatment with DMSO, apilimod (100 nM), or ESK981 (1000 nM) for 24 hours, binned as indicated. Bars are +/-SD. (Two-way ANOVA with Dunnett’s with DMSO as the baseline.). m . Total ion counts of individual isotopologues of C20 ceramide (d18:1/20:0) in 7940B cells upon incubation with U- 13 C 6 glucose and treatment with DMSO, apilimod (100 nM), or ESK981 (1000 nM). This is the pre-normalized data from (l) . Bars represent the range. n . C20 ceramide (d18:1/20:0) isotopologue distribution in 7940B cells upon incubation with 12 C 6 glucose and treatment with DMSO, apilimod (100 nM), or ESK91 (1000 nM) for 24 hours. Extraneous peaks were detected at M + 12-14 and M + 30-32 which are suspected to be contaminating species that were co-eluted with our target species. o . Fractional enrichment pattern in C22 ceramide (d18:1/22:0) in 7940B cells upon incubation with U- 13 C 6 glucose and treatment with DMSO, apilimod (100 nM), or ESK91 (1000 nM) for 24 hours. Bars represent the range. p . Data from (o) binned as indicated. Bars are +/-SD. (Two-way ANOVA with Dunnett’s.). q . Total ion counts of individual isotopologues of C22 ceramide (d18:1/22:0) in 7940B cells upon incubation with U- 13 C 6 glucose and treatment with DMSO, apilimod (100 nM), or ESK981 (1000 nM). This is the pre-normalized data from (o) . Bars represent the range. r . C22 ceramide (d18:1/22:0) isotopologue distribution in 7940B cells upon incubation with 12 C 6 glucose and treatment with DMSO, apilimod (100 nM), or ESK981 (1000 nM) for 24 hours. Extraneous peaks were detected at M + 12-14 which is suspected to be a contaminating species that were co-eluted with our target species. Statistics and reproducibility: b . n = 3 biological replicates. c . * indicates p < 0.05, ** indicates p < 0.01, *** indicates p < 0.001, **** indicates p < 0.0001. P-values: G6P: DMSO vs apilimod:9.0e-4; DMSO vs ESK981:2.6e-5; F6P: DMSO vs apilimod:5.5e-4; DMSO vs ESK981:2.6e-5; FBP: DMSO vs apilimod:0.007; DMSO vs ESK981:0.002; DHAP: DMSO vs apilimod:6.8e-6; DMSO vs ESK981:3.1e-7; G3P: DMSO vs apilimod:1.2e-4; DMSO vs ESK981:4.1e-5; 2PG: DMSO vs apilimod:8.2e-4; DMSO vs ESK981:7.2e-5; PEP: DMSO vs apilimod:6.9e-6; DMSO vs ESK981:1.5e-7. f-h . n = 4 biological replicates for DMSO and ESK981; n = 3 biological replicates for apilimod. i ; n = 4 biological replicates per group for AP, ESK, Fato, AP+Fato, and ESK+Fato groups, n = 3 for the DMSO group. j . n = 4 biological replicates per group for AP, ESK, Fato, AP+Fato, and ESK+Fato groups, n = 3 for the DMSO group. P-values: Ceramides: ESK981 vs ESK981 + fatostatin:2.6e-39. k . n = 3 biological replicates per group. l . n = 3 biological replicates per group. P-values: M + 10-M + 19: DMSO vs AP:0.031; DMSO vs ESK:0.040; M + 30-M + 38: DMSO vs AP:0.0021; DMSO vs ESK:0.034. m . n = 3 biological replicates each. o . n = 3 biological replicates per group. p . n = 3 biological replicates per group. P-value: M + 30-M + 40: apilimod vs DMSO:0.013. q . n = 3 biological replicates per group.

Article Snippet: C20 ceramide (d18:1/20:0) C 38 H 57 NO 3 (Cayman Chemicals) and C22 ceramide (d18:1/22:0) C 40 H 79 NO 3 (Cayman Chemicals) standards were dissolved in methanol at a concentration of 0.1 μg μl −1 and were used to confirm the identity of each species. (M + H) + , (M-H 2 O + H) + , (M + Na) + , (M + NH 4 ) + and (M-H) − were used to confirm the identity of each lipid species with mass accuracies of 5 ppm tolerance.

Techniques: Liquid Chromatography with Mass Spectroscopy, Two Tailed Test, Incubation